vimarsana.com
Home
Live Updates
Ipsen : and GENFIT enter into exclusive licensing agreement
Ipsen : and GENFIT enter into exclusive licensing agreement
Ipsen : and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership -Today at 07:50 am
Agreement gives Ipsen global1 rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis
...
Related Keywords
France ,
Macao ,
Macau General ,
Macau ,
Hong Kong ,
Pascal Prigent ,
Ipsen Euronext ,
David Loew ,
Terns Pharmaceuticals ,
European Medicines Agency ,
Euronext ,
Nasdaq ,
Drug Administration ,
European Commission ,
Primary Biliary Cholangitis ,
Breakthrough Therapy Designation ,
Orphan Drug Designation ,
Chief Executive Officer ,
Markets ,